Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to Sell Rating

Pulse Biosciences (NASDAQ:PLSE) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report issued on Monday.

Pulse Biosciences Stock Performance

Pulse Biosciences stock traded down $0.51 on Monday, hitting $16.09. 459,987 shares of the stock traded hands, compared to its average volume of 198,258. The business’s fifty day simple moving average is $18.78 and its 200 day simple moving average is $18.15. Pulse Biosciences has a 1 year low of $6.60 and a 1 year high of $25.00.

Institutional Trading of Pulse Biosciences

A number of hedge funds have recently made changes to their positions in PLSE. Invesco Ltd. increased its position in Pulse Biosciences by 1,956.7% during the 4th quarter. Invesco Ltd. now owns 214,490 shares of the company’s stock valued at $3,734,000 after buying an additional 204,061 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Pulse Biosciences by 15.1% during the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company’s stock valued at $19,958,000 after acquiring an additional 150,506 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after purchasing an additional 97,565 shares during the last quarter. State Street Corp boosted its stake in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares in the last quarter. Finally, Panoramic Capital LLC purchased a new stake in Pulse Biosciences during the 4th quarter valued at about $846,000. 76.95% of the stock is owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.